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Editorial on the Research Topic
Drug Development for Parasite-Induced Diarrheal Diseases
Diarrhea continues to be a major contributing factor to morbidity and mortality worldwide. It is
the second leading cause of death in children under 5 years old. Three enteroparasites, Entamoeba
histolytica, Giardia lamblia, and Cryptosporidium parvum are common infectious agents causing
persistent diarrhea. The Global Burden of Disease Study (GBDS) found that amebiasis was
responsible for more than 55,000 deaths and 2.2 million disability-adjusted life years (DALYs),
and cryptosporidiosis accounted for about 100,000 deaths and 8.4 million DALYs in 2010 (Hotez,
2014). According to theWHOFoodborne Disease Burden Epidemiology Reference Group (FERG),
giardiasis produced 171,100 DALYs in 2010 (Torgerson et al., 2015). Though giardiasis did not
result in deaths, the economic burden of acute giardiasis in the US continues to be substantial.
The annual cost involving the hospital based treatment for giardiasis is approximately $34 million
(Collier et al., 2012). In addition, E. histolytica, G. lamblia, and C. parvum are considered to be
bioterrorism threats by the National Institutes of Health (NIH) and Centers for Disease Control
and Prevention (CDC).
In absence of vaccines to prevent these parasitic diseases, control relies on chemotherapy which
is far from perfect and limited by adverse drug effects. For example, metronidazole is the most
common drug used to treat invasive amebiasis and giardiasis, but treatment often leads to side
effects, such as nausea, vomiting, diarrhea, or constipation. Moreover, potential resistance of E.
histolytica to metronidazole is an increasing concern. Although millions of people are infected by
E. histolytica each year, most individuals remain asymptomatic but may transmit amebiasis through
fecal excretion of infective cysts. Therefore, an additional drug paromomycin is required following
metronidazole treatment to eliminate cysts (Haque et al., 2003). However, treatment with two
drugs for 20 days is long, burdensome, and reduces compliance. In spite of the reported efficacy of
nitroimidazole drugs, treatment failures in giardiasis occur in up to 20% of cases and a recent report
from the Hospital for Tropical Diseases, London found that the nitroimidazole therapy failure rate
in giardiasis was 40.2% in 2013 (Nabarro et al., 2015). Nitazoxanide, the only treatment option for
cryptosporidiosis, has an efficacy ranging from 56% in malnourished children to 80% in healthy
adults and it is not effective for immunocompromised patients (Manjunatha et al., 2016). All these
factors make the development of new antimicrobials to treat these infections a critical need to avert
future outbreaks and deaths.
Recently, drug discovery efforts to treat parasite-induced diarrheal diseases are burgeoning.
Researchers across the globe are working toward identifying better drug candidates for the
treatment of these parasitic diseases. However, a comprehensive report of their endeavors
encompassing these parasites is lacking. We launched this Research Topic to compile the recent
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progress made by the parasitology research community to
develop effective drugs for the treatment of parasitic diarrheal
diseases. It may also provide a one-stop resource for drug
development research targeting enteric protozoan parasites.
Seventy-three authors enriched the Research Topic with their
contributions leading to 14 articles. These articles have been
organized in an e-book and can be categorized in four sections.
The first section opens with a review of different heterocyclic
compounds for their activity against intestinal protozoan
parasites, and current knowledge of the drug targets and
mechanism of action of some of the compounds (Azam et al.).
This review not only provides a survey of drug discovery research
on E. histolytica, G. lamblia, and C. parvum but also includes
an update on drug development for other intestinal parasites
such as microsporidia, Isospora and Cyclospora. A review article
by Miyamoto and Eckmann highlights different assays used for
drug development and detailed the implementation of both the
activity-centered and target-centered strategies to develop new
drug leads for cryptosporidiosis and giardiasis. The third article
of this section focused on repurposing of an FDA-approved
drug auranofin for the treatment of amebiasis and giardiasis
and the description of E. histolytica and G. lamblia thioredoxin
reductase as an attractive drug target (Andrade and Reed).
Auranofin showed promising activity against multiple parasites
and identifying a broad-spectrum antiparasitic agent may be a
useful drug discovery strategy for rare and neglected parasitic
diseases instead of applying “one bug-one drug” approach.
The second section includes five original research articles on
drug discovery for giardiasis. The articles range from medicinal
chemistry tomechanism of resistance studies and new drug target
identification. In the medicinal chemistry research article, the
authors synthesized 45 novel chalcone analogs with triazolyl-
quinolone scaffold and tested their activity against G. lamblia
(Bahadur et al.). Four compounds were particularly selective for
G. lamblia trophozoites with IC50 better than metronidazole and
less toxic against a human cell line. These new synthetic chalcone
derivatives hold promise for future design of antigiardial
compounds. Since resistance of Giardia to nitroimidazoles
and albendazole is an emerging issue, it is imperative to
understand the mechanisms involved in drug resistance in
order to develop better treatment strategies. Arguello-Garcia
et al. developed albendazole-resistant clones and compared the
expression of different antioxidant enzymes in albendazole-
sensitive and -resistant trophozoites. Albendazole was shown
to induce the formation of reactive oxygen species causing
DNA damage which led to apoptosis (Martinez-Espinosa et al.).
In contrast, albendazole-resistant trophozoites over expressed
antioxidant enzymes to detoxify reactive oxygen species. Two
articles exploited Giardiametabolic enzymes for parasite specific
drug development. An FAD-dependent glycerol-3-phosphate
dehydrogenase of G. lamblia was characterized for activity and
cellular localization (Lalle et al.). The authors validated the
target by inhibiting Giardia glycerol-3-phosphate dehydrogenase
activity chemically using an antitumor compound NBDHEX.
Guo et al. considered Giardia acyl-CoA synthetase (GiACS) as
potential drug target and recombinantly expressed GiACS1 and
GiACS2. Chemical inhibition of GiACS1 and GiACS2 activity by
an ACS inhibitor triascin C led to growth inhibition ofG. lamblia
trophozoites at low micromolar concentration. These studies
pave the way for future in vivo studies and also the development
of more potent inhibitors targeting these metabolic enzymes.
The year 2015 was particularly exciting for the parasitology
community because 2015 Nobel Prize in Physiology or Medicine
was awarded to three scientists who developed therapies against
parasitic infections. These drugs had their origin in microbial
and plant natural products. Our third section consists of four
articles on drug discovery for amebiasis. One article (Mori
et al.) was contributed by researchers of Kitasoto University and
National Institute of Infectious Diseases, Japan and included
Satoshi Omura as a co-author. Dr. Omura was awarded the 2015
Nobel Prize in Physiology or Medicine. This team screened the
Kitasoto Natural Products Library and extracts of 9,173 fungal
and actinomycete broths against two recombinant E. histolytica
cysteine synthases. Identification of deacetylkinamycin C and
nanomycin A as potent amebicidals may serve as a starting
point for natural product based drug discovery for amebiasis.
Identification of a protein that is involved in the virulence
and regulation of different stages of life cycle of a parasite
can aid in the development of new therapeutics. Singh et al.
showed the involvement of E. histolytica heat shock protein 90
(Hsp90) in regulation of phagocytosis and encystation. This study
together with a previous transcriptomic data of an increased
expression of Hsp90 during excystation indicate that E. histolytica
Hsp90 can be a promising therapeutic target. Shahinas et al.
further validated the importance of parasite Hsp90 as a drug
target by identifying five compounds that targeted E. histolytica
Hsp90 and inhibited the growth of E. histolytica trophozoites.
Though no E. histolytica clinical isolates with high levels of
metronidazole resistance have been detected, reliance on a single
drug for more than 50 years puts them at increased risk to
develop drug resistance. Even a low level of metronidazole
resistance in the culture led to several cellular changes in E.
histolytica such as lower rates in growth, adhesion, phagocytosis,
cytopathogenicity, and glucose consumption (Penuliar et al.).
Transcriptional profiling identified genes related to oxidative
stress, nucleotide binding, metabolism, and signal transduction
that were differentially expressed in the resistant parasite
(Penuliar et al.). This study should serve as a cautionary advice
on the importance of continuing the search for an alternative
drug.
The final section deals with an assay development for a
C. parvum drug screen and identification of a new lead for
the treatment of cryptosporidiosis. An improved and simplified
qRT-PCR based assay was developed and made amenable to
high-throughput screen for C. parvum (Zhang and Zhu). The
assay was validated by screening a small set of compounds.
Sonzogni-Desautels et al. identified oleylphosphocholine as a
new drug lead for C. parvum infection. Oral treatment with
40 mg/kg/day of oleylphosphocholine cured the infection in
immunocompromised mice and provided protection up to 30
days. It remains to be seen if similar protection can be achieved in
immunocompetent mice. Still this is an encouraging finding for
the development of future treatment in immunocompromised
patients.
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Together, this Research Topic provided the current status
of drug discovery research in parasitic diarrheal diseases and
covered a wide-spectrum of topics from traditional drug
discovery method to target identification and mechanism of
resistance.
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